Singer Instruments

Executive Summary

Singer Instruments, a privately held UK company founded in 1984, is a leading provider of laboratory automation solutions for synthetic biology. With over 1,000 installations in 60 countries and more than 10,000 scientific citations, the company has established a strong global footprint. Its mission to accelerate research by developing automation tools for scientists aligns with the growing demand for high-throughput workflows in synthetic biology, drug discovery, and agricultural biotech. Despite a lack of disclosed financial details, Singer’s sustained presence over four decades and widespread adoption suggest a resilient business model and deep customer loyalty. The company operates in a niche but expanding market, benefiting from increasing R&D investment in bioengineering and the push for reproducible, scalable lab processes. However, as a private entity, visibility into near-term growth drivers is limited, and competition from larger life sciences tools companies poses a constant threat. Overall, Singer Instruments occupies a defensible position in a high-growth sector, with potential for steady revenue growth driven by recurring consumables and service contracts.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation automated colony picking & arraying platform60% success
• H2 2026Strategic partnership with a major synthetic biology CDMO45% success
• Q4 2026Expansion into Asian markets via new distribution agreements70% success